/RVLP

RVLP Stock - RVL Pharmaceuticals plc

Q: What is the analyst price target for RVLP?

Analyst price target information is not currently available for RVLP.

Q: What is RVLP's market cap?

Market capitalization information is not currently available for RVLP.

Healthcare|Biotechnology|NASDAQ

$0.03-32.05%

$0.01 (-32.05%) • Oct 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.03

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RVLP

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.09

52W High$1.66

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$49.72M	$17.50M	$27.76M	$240.03M	$263.70M
Gross Profit	$40.27M	$13.88M	$24.47M	$128.40M	$123.62M
Gross Margin	81.0%	79.3%	88.1%	53.5%	46.9%
Operating Income	$-45,680,000	$-80,510,000	$-61,742,000	$3.94M	$-98,537,860
Net Income	$-51,692,000	$-82,849,000	$-89,013,000	$-270,901,000	$-109,680,741
Net Margin	-104.0%	-473.4%	-320.6%	-112.9%	-41.6%
EPS	$-0.58	$-1.23	$-1.47	$-5.17	$-2.42

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 8765.2% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 21st 2022	Jefferies	Resumed	Hold	$2.5

Earnings History & Surprises

RVLP

Beat Rate

47%

Last 17 quarters

Avg Surprise

-118.0%

EPS vs Estimate

Beats / Misses

8/7

2 met exactly

Latest EPS

$-0.16

Q4 2023

EPS Surprise History

Q1 22

+10.3%

$-0.26vs$-0.29

Q2 22

+48.0%

$-0.13vs$-0.25

Q3 22

+20.8%

$-0.19vs$-0.24

Q4 22

+15.8%

$-0.16vs$-0.19

Q1 23

-20.0%

$-0.18vs$-0.15

Q2 23

0.0%

$-0.12vs$-0.12

Q3 23

0.0%

$-0.13vs$-0.13

Q4 23

-45.5%

$-0.16vs$-0.11

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 12, 2024	—	—	—	—
Q2 2024	May 9, 2024	—	—	—	—
Q1 2024	Mar 18, 2024	—	—	—	—
Q4 2023	Nov 9, 2023	$-0.11	$-0.16	-45.5%	✗ MISS
Q3 2023	Aug 14, 2023	$-0.13	$-0.13	0.0%	= MET
Q2 2023	May 11, 2023	$-0.12	$-0.12	0.0%	= MET
Q1 2023	Mar 20, 2023	$-0.15	$-0.18	-20.0%	✗ MISS
Q4 2022	Nov 10, 2022	$-0.19	$-0.16	+15.8%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.24	$-0.19	+20.8%	✓ BEAT
Q2 2022	May 12, 2022	$-0.25	$-0.13	+48.0%	✓ BEAT
Q1 2022	Mar 30, 2022	$-0.29	$-0.26	+10.3%	✓ BEAT
Q4 2021	Nov 15, 2021	$-0.31	$-0.28	+9.7%	✓ BEAT
Q3 2021	Aug 16, 2021	$-0.14	$-0.28	-100.0%	✗ MISS
Q2 2021	May 13, 2021	$-0.23	$-0.15	+34.8%	✓ BEAT
Q1 2021	Mar 30, 2021	$-0.24	$-0.88	-266.7%	✗ MISS
Q4 2020	Nov 10, 2020	$-0.20	$-0.14	+30.0%	✓ BEAT
Q3 2020	Aug 11, 2020	$-0.12	$-0.22	-83.3%	✗ MISS
Q2 2020	May 12, 2020	$-0.14	$-0.05	+64.3%	✓ BEAT
Q1 2020	Mar 18, 2020	$-0.06	$-0.51	-750.0%	✗ MISS
Q4 2019	Nov 14, 2019	$-0.20	$-2.15	-975.0%	✗ MISS

Frequently Asked Questions about RVLP

What is RVLP's current stock price?

RVL Pharmaceuticals plc (RVLP) is currently trading at $0.03 per share. The stock has moved -32.05% today.

What is the analyst price target for RVLP?

No analyst price targets are currently available for this stock.

What sector is RVL Pharmaceuticals plc in?

RVL Pharmaceuticals plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is RVLP's market cap?

RVL Pharmaceuticals plc has a market capitalization of $0.00 billion, making it a small-cap company.

Does RVLP pay dividends?

No, RVL Pharmaceuticals plc does not currently pay a dividend to shareholders.